Hence, molecular epidemiological studies targeting HBx genetic variability and occurrence of AFB1 induced p53 mutations may be helpful in assessment and surveillance of HCC risk in regions where chronic HBV and AFB1 exposure is high. The gene discussed is TP53; the disease is hepatocellular carcinoma.